221 related articles for article (PubMed ID: 29513203)
1. Disopyramide use in infants and children with hypertrophic cardiomyopathy.
O'Connor MJ; Miller K; Shaddy RE; Lin KY; Hanna BD; Ravishankar C; Rossano JW
Cardiol Young; 2018 Apr; 28(4):530-535. PubMed ID: 29513203
[TBL] [Abstract][Full Text] [Related]
2. Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.
Adler A; Fourey D; Weissler-Snir A; Hindieh W; Chan RH; Gollob MH; Rakowski H
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28550094
[TBL] [Abstract][Full Text] [Related]
3. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
Haruki S; Minami Y; Suzuki A; Hagiwara N
Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
[TBL] [Abstract][Full Text] [Related]
4. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
[TBL] [Abstract][Full Text] [Related]
5. Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy.
Topriceanu CC; Field E; Boleti O; Cervi E; Kaski JP; Norrish G
Int J Cardiol; 2023 Jan; 371():523-525. PubMed ID: 36174821
[TBL] [Abstract][Full Text] [Related]
6. Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy.
Habib M; Hoss S; Bruchal-Garbicz B; Chan RH; Rakowski H; Williams L; Adler A
Int J Cardiol; 2019 Dec; 297():75-82. PubMed ID: 31615649
[TBL] [Abstract][Full Text] [Related]
7. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy.
Sherrid M; Delia E; Dwyer E
Am J Cardiol; 1988 Nov; 62(16):1085-8. PubMed ID: 3189171
[TBL] [Abstract][Full Text] [Related]
8. Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.
Tokudome T; Mizushige K; Ueda T; Sakamoto S; Matsuo H
Angiology; 1999 Apr; 50(4):331-5. PubMed ID: 10225470
[TBL] [Abstract][Full Text] [Related]
9. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
Kajimoto K; Imai T; Minami Y; Kasanuki H
Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
[TBL] [Abstract][Full Text] [Related]
10. Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.
Sirak TE; Sherrid MV
Chest; 2008 May; 133(5):1243-6. PubMed ID: 18460523
[TBL] [Abstract][Full Text] [Related]
11. Impact of gender on the left ventricular cavity size and contractility in patients with hypertrophic cardiomyopathy.
Dimitrow PP; Czarnecka D; Strojny JA; Kawecka-Jaszcz K; Dubiel JS
Int J Cardiol; 2001 Jan; 77(1):43-8. PubMed ID: 11150624
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
[TBL] [Abstract][Full Text] [Related]
13. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children.
Duncan WJ; Tyrrell MJ; Bharadwaj BB
Can J Cardiol; 1991 Mar; 7(2):81-6. PubMed ID: 2049687
[TBL] [Abstract][Full Text] [Related]
14. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy.
Kimball BP; Bui S; Wigle ED
Am Heart J; 1993 Jun; 125(6):1691-7. PubMed ID: 8498312
[TBL] [Abstract][Full Text] [Related]
15. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
Verlinden NJ; Coons JC
Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
[TBL] [Abstract][Full Text] [Related]
16. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy.
Shelke AB; Menon R; Kapadiya A; Yalagudri S; Saggu D; Nair S; Narasimhan C
Indian Heart J; 2016; 68(5):618-623. PubMed ID: 27773399
[TBL] [Abstract][Full Text] [Related]
17. [Doppler and echocardiographic assessments of effects of disopyramide on non-obstructive hypertrophic cardiomyopathy].
Nagashima J
J Cardiol; 1991; 21(1):75-86. PubMed ID: 1817183
[TBL] [Abstract][Full Text] [Related]
18. [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
Terrosu P; Franceschino V; Contini GM; Dore L; Ibba GV
G Ital Cardiol; 1984 Jan; 14(1):63-6. PubMed ID: 6538527
[TBL] [Abstract][Full Text] [Related]
19. Verapamil therapy in infants with hypertrophic cardiomyopathy.
Moran AM; Colan SD
Cardiol Young; 1998 Jul; 8(3):310-9. PubMed ID: 9731645
[TBL] [Abstract][Full Text] [Related]
20. Fixed left ventricular outflow tract obstruction mimicking hypertrophic obstructive cardiomyopathy: pitfalls in diagnosis.
Ayoub C; Brieger D; Chard R; Yiannikas J
Echocardiography; 2016 Nov; 33(11):1753-1761. PubMed ID: 27613242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
